Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

← catalyst calendar

NCT03894215

Sponsored by Agenus Inc. (industry) · AGEN — their whole pipeline →. With GOG Foundation.

Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
211actual
Sites
68
Countries
Brazil, Mexico, Peru +4

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Sponsor strategic decision

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2019-06-01actualWhen the study began enrolling
Primary completion2025-03-26actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-03-26actualThe whole study's end, after follow-up
First posted2019-03-28actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-03-27actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Cervical Cancer

Interventions

  • Drug: AGEN2034
  • Drug: AGEN1884

Primary outcome

what the primary-completion date above is the date OF
Objective Response Rate
measured 48 months

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AGEN's whole pipeline · Catalyst calendar · Every registered study · What changed